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Biotechnology is widely attracting attention as a generic technology used in many different industry
sectors. This paper deals with biotechnology in the pharmaceutical industry in the Netherlands, by
focusing on the spatial pattern of firms and on business strategies of an important segment, namely
independently established firms. The pharmaceutical industry is relevant because it is expected to
become the leading sector in the application of biotechnology in the near future.
The paper first discusses the theoretical basis for the interpretation of the location pattern of firms
and the latter’s strategies, i.e. evolutionary approaches. Further, it pays attention to the selection
environment by focusing on market and technology trends, and institutional factors. These trends
and factors are then linked with opportunities and threats for the application of biotechnology by
small firms. Against this background, various strategies for survival are analysed, such as connected
with uncertainty in R&D, shortage of finance and expertise, and lack of access to global distribution
networks. Particular attention is paid to collaborative agreements with larger firms. The empirical
part of the study is based on statistics covering the sector, as well as in-depth interviews with on-
site managers of small firms.
Keywords: biotechnology, pharmaceutical industry, location pattern, the Netherlands, survival
strategies, evolutionary approaches.2
1. Introduction
Biotechnology is a broad generic technology; it is the application of scientific and engineering
principles to the processing of materials by biological agents. By using this broad definition,
biotechnology encompasses processes based on fermentation, cell culture and bio-catalytic
principles, and those areas of biomedicine and agriculture which involve the application of cellular
or molecular biology. Accordingly, biotechnology includes old activities like brewing and microbial
production of antibiotics, alongside new activities. In a narrow sense, biotechnology is confined to
those technologies connected with recombinant DNA-techniques and cell fusion (OECD, 1989).
More recent definitions include combinatorial chemistry as a technique, as well as genome analysis.
In the context of health care, the latter aims to depict the genetic sequence variation in humans, as
the basis for variation in risks among individuals for medically important diseases. A relatively new
term is life sciences (Ernst & Young, 1997). This encompasses new application fields like
renewable resources and environmental affairs, aside from health care and animal health, agriculture
and food processing
One of the key discoveries has been recombinant DNA technology (1973) which allows direct
manipulation of the genetic material of individual cells. The ability to determine which genes are
used by cells enables more control over the production of biological molecules than ever before.
Thus, recombinant DNA technology can be used to develop micro-organisms that produce new
products, existing products more efficiently, or large quantities of otherwise scarce products. It can
also be used to develop organisms that are useful themselves, e.g. micro-organisms that degrade
toxic waste, or new strains of agriculturally important plants. It needs to be emphasised that the
commercial success of specific applications of recombinant DNA and other techniques depends
critically on advances in bio-process engineering. Bio-process technology allows the adaptation of
biological methods of production (such as single batches) to large-scale industrial use.
Basic research in biotechnology occurs mainly in the publicly funded science base, although
industrial partners may be involved. Small specialist firms have historically been most effective in
converting scientific discoveries into product and service ideas with commercial potentials. These
firms have the flexibility to transcend disciplinary boundaries which are basically structuring R&D3
departments and activity of large pharmaceutical firms. In addition, many large firms moved back to
their core competence since the mid 1970s, times in which it was difficult to allocate budgets to
entirely new technologies with highly uncertain outcomes. Although certain large pharmaceutical
firms have developed in-house biotechnology R&D, there is an important role for the small firms'
segment.
Nowadays, biotechnology is an important integral part of many industry products and processes
(Ballentine and Thomas, 1997). The above discussion on terminology indicates that researchers
come up with different statistical data on the size of the biotechnology sector, dependent on the
definitions used. By using a broad definition of life science industry and confining this to small and
medium-sized enterprises (excluding chemical and pharmaceutical multinationals), it is estimated
that the sector encompasses almost 1,200 firms in Europe and almost 46,000 jobs here (Ernst &
Young, 1999) (Table 1). Revenues  amount to 3,7 billion ECU and investments in R&D to 2,3
billion ECU.
Table 1 Entrepreneurial firms in Europe and United States of America (1998)
Indicator Europe    US
Revenues (a)   3,709   15,777
R&D expense (a)   2,334     8,398
Number of firms   1,178     1,283
Employees 45,823 153,000
(a) Euro in millions.
Source: Ernst & Young’s European Life Sciences 1999.
The US has been more successful than Europe in creating a new industry based on biotechnology.
Europe has partly missed the first wave of new specialist firms in the early 1980s exemplified by
American Genentech, Cetus and Centocor (Daly, 1985). The relatively late take-off in Europe has
caused a much smaller size of the present biotechnology-based industry compared with the US,
such as in terms of revenues (3,7 versus 15,8 billion ECU) and employment (46,000 versus
153,000 employees). Europe's position seems now improving, particularly in terms of number of
firms (witness a growth in 1998 by 14% versus 1% in the US) (Ernst & Young, 1999).4
The Dutch biotechnology sector is relatively small with around 65 firms in all size classes and fields.
There are no global players as far as the pharmaceutical industry is concerned. Dutch firms have,
however, good opportunities to take niche positions due to a well-developed science base in the
Netherlands. The latter includes important publicly funded research institutes, as well as well as an
internationally advanced infrastructure for clinical testing (Ministry of Economic Affairs/Booz,
Allen & Hamilton, 1993). With regard to the future use of biotechnology, it is expected that the
contribution to the pharmaceutical sector will be the largest of all sectors in 2010 (Table 2). In the
Netherlands, experts estimate shares of 34% and 38%, with agriculture as the second largest sector
(20% and 38%).
Table 2  Percent share of biotechnology in turnover in sectors in the Netherlands (a)
SECTOR 1996
I      E
2010
I      E
Pharmaceutical  9     10 34   38
Agriculture  2      9 20   38
Food  3      6 30   25
Chemicals 13     6 27   20
Environment  9      4 18   21
a. Estimates by experts, from the sector itself (I) and from the remaining sectors (E).
Source: Degenaars and Janszen, 1996.
2. An Evolutionary Approach
In management and innovation studies there is now a growing attention for evolutionary
approaches, particularly concerning the interaction between firms and their environment over time
(Baaij and van den Bosch, 1999; Douma and Schreuder, 1998). In highly innovative environments
firms have to adapt themselves continuously, not only because of risks from a fast changing
technology but also institutional factors (regulation) that cannot keep pace with new technology.
Given such dynamics, evolutionary approaches seem rather useful in the analysis of the
establishment and survival of firms in connection with opportunities and threats in their5
environment. Evolutionary approaches seek to explain the movement of an entity (or entities) over
time and the causes of the state of an entity at a moment in time in terms of how this entity got
there. In addition, it puts an emphasis on the different adaptation of entities to changes in the
selection environment (Nelson and Winter, 1982; Silverberg et al., 1988; Dosi and Nelson, 1994).
While major steps have been taken by Nelson and Winter in the early 1980s, there is currently a
new wave of evolutionary theorising (cf. Dosi and Nelson, 1994; Cimoli and Dosi, 1995). This is
fostered by various converging factors, such as the recognition of the difficulties of equilibrium
theory - and the concept of perfectly rational actors - in the interpretation of wide fields of
economic behaviour, the providing of useful heuristics for applied research, and the contribution of
applied research to inductive generalisations from which evolutionary theory can draw behavioural
assumptions. Evolutionary economic approaches provide the following important notions, more or
less in analogy with evolutionary biology (Nelson and Winter, 1982; Metcalfe and Gibbons 1986;
Arthur 1994; Dosi and Nelson, 1994):
• Firms embody the units of selection (equivalent of genes), such as technologies, strategies,
and inherent preferences. Accordingly, firms are subject to various types of selection with
the market as the single most important selection environment. In addition, there are
selection environments such as government regulation and patenting regimes (institutions).
Competition is the major mechanism of selection; there is competition with regard to
market share and with regard to access to scarce resources (Pfeffer and Salanchik, 1978).
Threats emerge from suppliers, customers, and new entrants, as well as substitute products
and new technologies. Competition may lead to closure of weak performing firms through
failure (bankruptcy) or acquisition by stronger firms.
• Different from Darwinian theory, the survival of strong firms does not rest on mutation by
chance but on a more or less active adaptation to the environment. Accordingly, firms are
seen as entities displaying purposeful behaviour and adapting themselves to the
environment, as well as changing the environment to their needs (Baaij and van den Bosch,
1999). Fitness is the extent to which firms interactively adapt themselves to the multiple
selection environment. The adaptation process is mainly directed by routines, i.e. forms of6
rule-guided behaviour that are largely invariant to fine changes in the environment.
Routines are based upon the learning history of the firm and pre-existing knowledge, and
are associated with incremental adjustments, i.e. close to pre-existing patterns. Accordingly,
firms' behaviour is largely path-dependent. Path dependency is the situation in which it is
difficult to abandon once selected directions (e.g. technologies, product-markets) due to an
accumulation of experience, routines (and networks) and capital in the recent past (Arthur,
1994).
• According to particular theorising in regional economics, path dependency in a spatial form
tends to influence the location of new technology and new technology-based firms. This
process is caused by the principle of increasing returns on investments and manifests itself
in agglomeration economies, such as from the availability of highly specialised labour,
knowledge and research infrastructure, and the proximity of specialised suppliers and
customers. Accordingly, new technologies preferably emerge where the local selection
environment provides a number of positive external economies and this is often based on
existing structures (Boschma and Lambooy, 1998). In addition, it is recognised that
stochastic developments may take place leading to unexpected concentrations of new
technology.
• In selection environments where market competition is strong and R&D expensive and full
of risks, the best mode of co-existence of firms with different needs and capabilities is to
develop collaborative relationships, such as based on complementarity. Sometimes,
relationships based on interdependence tend to the development of complex forms of
symbiosis, a state in which no single firm can be considered in isolation.
• Some evolutionary models emphasise that particular firms look forward to anticipate future
developments, while other firms do not (Silverberg et al., 1988). Accordingly, there are
offensive firms (breaking new grounds) and defensive firms. A similar typology is
recognised in theories about innovative behaviour (Freeman, 1982), i.e. first innovators and
followers, and non-innovators. First innovators aim to maintain a lead over innovative
competitors. This strategy is costly in terms of research efforts and risky in that the
technology can fail or can be overruled by a superior adapted technology, but profits may
be high after some painful first years. The point here is the recognition of diversity between7
firms in their preferences and capability for adaptation.
Against the above theoretical background, the study addresses the location pattern of bio-
pharmaceutical firms in the Netherlands and their strategies for survival, given different
opportunities and threats in the selection environment. The analysis of the location pattern is based
on data including all relevant firms in the Netherlands (Note 1). As indicated previously, there is an
important definition problem influencing statistics about the industry. Based on various sources, 34
bio-pharmaceutical firms can be identified in this study by excluding other types of biotechnology
industry like food and agriculture, and environmental biotechnology. Mere trade firms are also
excluded. Different from the category of entrepreneurial firms mentioned in the introduction, large
and medium-sized multinationals are included in our database (such as Akzo Nobel Pharma and
Solvay) because they are potential places where new technology emerges (Table 3). In the
Netherlands, the share of these firms is relatively small (17.6%). A majority of the bio-
pharmaceutical firms can be qualified as independently established (61.8%). These firms are often
relatively young and small.
Table 3 Dutch bio-pharmaceutical  industry according to firm type
Firm Type Absolute    Percentage
number      share
Established multinational
Newly established  (foreign)
subsidiary
    6             17.6
 
    7              20.6
Independently established   21              61.8
Totals   34            100.0
The exploratory analysis of survival strategies in this study is based on various sector studies (e.g.
Degenaars and Janszen, 1996; Ernst & Young, 1997/99) and on five in-depth case studies of small
bio-pharmaceutical  firms. Desk research (company documents, branch journals) and interviews
with corporate managers at two points in time (around 1990 and in 1998) have been the main
information sources. The analysis here is largely confined to independently established firms.
3. Opportunities8
In the pharmaceutical industry one can identify three major trends indicating an important role for
new bio-pharmaceutical firms. First, there is an ongoing process of merging and acquisition
between large pharmaceutical firms. This development leads to a concentration of R&D and an
outflow of highly qualified researchers. A good example is the merger of Swiss Sandoz and Ciba-
Geigy, with the establishment of various small firms by former employees as a logical consequence.
Secondly, among large pharmaceutical firms there is an increased preference for co-operation with
small biotechnology firms (strategic alliances). Large firms need new ideas and products that
witness clear market potentials at the same time that they avoid to cover a large repertoire of
different technologies in-depth (the strategy to remain mean and lean) (NEFARMA 1998).
Accordingly, it is expected that the pharma industry will spend up to a maximum of 30 percent of
its drug discovery budgets for external collaboration (Ernst & Young, 1999). Thirdly, there is an
important application of biotechnology in the development of new drugs for disease for which no
effective therapy is available thus far. This is connected with the coming depletion of traditional
development paths and the coming expiring of patents for traditional drugs. Regarding the latter,
various major firms will see a huge proportion of their drug sales hit by patent expires in the next
coming years. For example, more than half of Lilly’s sales comes from products which face patent
expiry by 2003. For Merck & Co this is true for nearly half of its sales (Ernst & Young, 1999).
New biotechnology offers various opportunities regarding the wide range of different
technologies as well as the new combinations derived from them. When considering the
technologies used in Dutch bio-pharmaceutical firms it becomes apparent that there are many







• Cell/tissue culture and engineering9
• Cell fusion technology
• Monoclonal and polyclonal antibodies
• Labelling of DNA and antibodies
• Protein engineering
A further interesting development is the merging of formerly separated technologies, leading to a
range of new products, processes and services. A good example is the diagnostic kit and its use,
combining information technology, micro-electronics and biotechnology in diagnostics. A further
example is genomics, combining gene research with a highly intensive use of information
technology and mathematics.
Another favourable condition in the selection environment in the Netherlands is the production of
excellent knowledge in relevant fields by universities. In a comparative study between European
metropolitan areas, cities like Amsterdam, Leiden and Utrecht rank high in the quality of their
academic research, such as in molecular biology, immunology, and biochemistry (Science, August
1998). Given this situation in knowledge supply, alongside the favourable conditions for clinical
trials, the relatively small number of bio-pharmaceutical firms points to a shortage of entrepreneurs
that can transform scientific ideas into marketable products or processes. This phenomenon can be
ascribed to a great deal of risks, to be discussed in the next section. 
In terms of institutional trends, there is an ongoing government pressure to reduce expenses in
human healthcare (van Geenhuizen and van der Knaap, 1997). This pressure manifests itself in a
growing prescription of (relatively cheap) generic drugs and in price-reductions of patented drugs,
leading to smaller revenues for basically innovative firms. This may work in favour of
biotechnology firms regarding their potential to contribute to the introduction of more efficient and
cheaper production processes. The policy for cost saving in healthcare manifests itself also in a
decrease of consulting medical specialists. This leads to an increased demand for 'near patient-tests',
often based on biotechnology.
4. Threats from a small firm’s perspective10
This section identifies various threats in the application of biotechnology in the pharmaceutical and
medical sector in the Netherlands by considering young start-ups (Degenaars and Janszen, 1996;
Ernst & Young, 1999). The threats are all very basic and usually much stronger than in other high
technology sectors:
• The uncertain nature of research outcomes. In some cases, there is the threat of an entire
failure. This is quite risky, given the fact that the development of a modern biomedical drug
takes on average 10 years, including approval by regulatory authorities. At the same time,
attention for particular technologies may be subject to swift change. For example, nowadays
genomics and combinatorial chemistry increase in importance in the development of new
therapeutic drugs, being almost unknown a few years ago.
• Uncertainty from the time of emergence of the marketable product (process). It often happens
that the novel product or process emerges too early compared with market demand. This may
be due to negative public opinion or a lack of context in which the discovery would fit.
• A shortage of equity capital in particular development stages. This refers mainly to basic
research firms for which the period without profits is often longer than expected. It is also true
for the stage in which small firms move to manufacturing and need capital for a production
plant. At early stages of development, there is usually no shortage of investment capital in the
Netherlands. Investments stem from individuals (founders, business angels), venture capitalists
or strategic corporate partners. In later stages, public offering may be a solution but access to
the Official Market of Amsterdam Exchange (AEX) is difficult due to various limitations. It is
only very recently that two newly established exchange markets take account of the particular
conditions of  young  fast growing firms (NMAX and EASDAQ) (Note 2).
• A shortage of specific expertise and experience. The application of biotechnology is a critical
combination of different disciplines, like genetics, biochemistry, manufacturing under
pharmaceutic rules, and entrepreneurial management. A shortage of the latter is often the key
problem. Managing a bio-pharmaceutical firm means managing a number of paradoxes that may
change in the course of time. For example, the entrepreneurial drive to launch a firm does not
necessarily match with the ability to negotiate the financing by venture capitalists and securing
interest from large pharmaceutical firms. The former aims at a safe use of their investments,11
whereas the latter aims at innovation and creativity.
• A shortage of qualified personnel in the local (regional) labour market. This becomes apparent
when a facility for manufacturing is planned and holds particularly for qualified laboratory
analysts.
• Difficulties in finding access to global distribution outlets. Marketing and sales in the
pharmaceutical industry are dominated by large firms that can afford the huge expenses for these
activities on a global scale. Bio-pharmaceutical firms usually decide not to become an integrated
firm, meaning that for marketing and sales they have to rely on other parties, often large
pharmaceutical firms.
• Uncertainty in intellectual property protection. Small firms struggle with the dilemma whether
to invest large amounts of time and capital in patent protection and potentially benefit from
revenues from licensing, or do nothing and save time and money. A further danger is the small
evidence about what can and what cannot be protected by patents, including the lack of
European patent regulation. Since May 1998, the situation has improved significantly when the
European Parliament passed legislation that makes human gene sequences and transgenic plants
patentable under particular conditions. However, the EU directive on patents will be postponed
in the Netherlands due to procedural mistakes (Ernst & Young, 1999).
• Legal barriers to the use of transgenic animals for research. Transgenic animals are seen as
helpful and (in the future) cheap devices to produce certain compounds for human drugs. There
are, however, ethical objections against such use of transgenic animals. A new law on the health
and well-being of animals may cause important barriers in this particular field. The current Dutch
policy can best be described as: “no, unless specifically approved by a committee”(Ernst &
Young, 1999).
The above overall picture indicates various serious uncertainty in the early years and some later
development stages of bio-pharmaceutical firms. When such situations of uncertainty coincide or
accumulate, survival becomes questionable. As discussed in Section 2, evolutionary reasoning
indicates that various uncertainty costs may be reduced by benefiting from external economies in
existing clusters of (dis)similar firms and institutes.12
5. Location Pattern
The main characteristics of the location of new bio-pharmaceutical technology in the Netherlands
can be summarised as follows (Table 4):
• In terms of shares, the new technology has emerged in an almost even pattern in cities of
different size. Only small medium-sized towns account for a relatively large part of the firms
(38.2%). With regard to the regional distribution, the metropolitan region of the Randstad
accounts for a small majority (58,8%).
• In terms of concentration, larger medium-sized towns are most important with large cities in
second place (concentration quotients of 29.4 and 22.0 respectively).
• The most important larger medium-sized town is Groningen located at a distance from the
metropolitan region of the Randstad; the most important large city is Amsterdam located in the
Randstad.
The above pattern partly follows the existing spatial distribution of pharmaceutical industry (van
Geenhuizen and van der Knaap, 1997) with concentrations both in the Randstad (medium-sized
towns and large cities) and the adjacent zone. This confirms the reasoning in evolutionary
approaches in that new technologies preferably emerge on the basis of existing patterns. However,
at the same time, the spatial distribution points to an “unexpected” cluster of bio-pharmaceutical
firms in the Northern part of the country.




   (1)
Percentage of firms
  (2) (b)
(2) : (1)
< 50  91.1   14.7   (5.9)     0.2
  50 – 100    5.3   14.7   (8.8)     2.8 
101 – 150    2.4   38.2  (26.5)   15.9
151 – 200    0.5   14.7    (0.0)   29.4
201 – 800    0.8   17.6  (17.6)   22.0
  
Totals 100.0  100.0  (58.8)   -
a. N  = 34.
b. Within brackets is the percentage of firms per size-class located in the metropolitan area 
of the Randstad.13
The following factors can be forwarded as favourable in Groningen and different from the
Randstad. First, Groningen is located in a region that benefits from subsidies in the context of
European regional policy and Dutch national regional policy. Subsidies may help to establish
incubator buildings and provide relatively cheap premises. Secondly, actors in the academic world
together with financiers and consultants in Groningen seem particularly active in identifying
marketable innovative ideas (products) and providing opportunities to bridge the gap between such
ideas and market introduction (van Geenhuizen, 1996). It may be that such an “entrepreneurial
elan” can relatively easily flower at a university in an area without competing initiatives from other
universities.
6. Survival Strategies
The results of the case study analysis indicate a large differentiation between firms regarding the
level of innovativeness and risk taking, both at one point in time and in the course of time. The
findings point to the following types of firm (Table 5):
• Firms engaged in basically innovative R&D over a long time period. They take large risks,
including a considerable period without profits (such as firm A).
• Firms that manufacture an established product almost from their start. The present
development activity aims at minor product improvement (new product types), and hence
these firms are less innovative and take smaller risks (such as firm C).
• Firms that have been highly innovative in their first 5 to 10 years. Nowadays, they are
engaged in development activity and manufacturing by contract from other companies and
institutes. They reduce risks from the market by working by contract and on customer
specification (such as firm B and E).
• Firms engaged in the development and manufacturing of innovative products, while
contracting out basic research as well as manufacturing (such as firm D around 1990).
These firms are like virtual firms.
It is quite clear that only the first type bears large risks in terms of highly uncertain outcomes of14
R&D over a long time  Furthermore, it is interesting to see that small firms create various options
to avoid risks in the initial stages, such as to undertake research exclusively by contract from other
parties, to refrain from the most risky activities by contracting them to others, or to conduct risky
activities by themselves but making use of laboratory equipment at universities. A further option is
to add 'safe' activities in such a way that the innovative R&D can be financed internally.
Accordingly, sales of accepted products from other manufacturers or relatively simple contract
research may be added (Walsh, 1993; Feldman, 1998).
Aside from internal financing, capital in the initial stages is usually available from venture capital
banks or informal investors. However, problems may arise when the R&D stage needs to be
extended because of lack of results or when the firm needs to move to manufacturing activity under
pharmaceutical rules. In these situations, there are three ways to attract capital while remaining
independent, namely from investment banks, from a flotation on exchange markets, and from a
large partner. In all cases, trust in the firm's fortune is of crucial  importance. Accordingly, the best
time for attracting equity capital is shortly after a major success has been achieved in the R&D.
Thus, firm A has communicated its success in breeding transgenic animals in the press in Spring
1998 while planning flotation on the AEX later in the year. This illustrates the need for a creative
interplay between R&D planning, financial planning, and public relations aimed at gaining
credibility. Firm A also exemplifies a strategy in response to potential barriers from laws on the
well-being of animals. The firm operates laboratories in various countries, which enables a move of
the activity to a country without such barriers.
Regarding the need for specific expertise and experience, a good strategy is to establish a firm with
a minimum of two founders, each with different crucial knowledge. Survival may be enhanced
when the managing director has both experience in the technology and in entrepreneurial
management of a pharmaceutical firm. Firm D exemplifies a situation in which the latter experience
was absent among the founders. As a result, the investment banks involved in the through-start
forced the firm to find a managing director offering such a combination of experience. Firm D also
illustrates the need for in-house expertise in financial management.15
It is almost crucial that small firms hold strategic positions in knowledge networks. This touches
upon the following point. As indicated before, developments in biotechnology are risky in terms of
uncertain outcomes and unforeseen changes. Path-dependency as a natural tendency of firms,
therefore, needs to be avoided by a high alertness and easy access to the newest information. In
addition, investments that 'fix' the direction in research of a firm for many years need to be avoided.
Firm D exemplifies this avoidance by contracting research requiring a highly expensive
infrastructure to other parties (public laboratory). There is, however, a need for a balance between
core-activity and activity contracted to others. Firm D may have broken this balance and lost core-
competence, a situation that probably contributed to its bankruptcy. The issue of path dependency
is also relevant from another perspective. It seems that firms that were low innovative in their initial
stages, tend to extend their activities later-on with low innovative products. The danger seems to be
similar to the previously mentioned one, namely a loss of core-competence.
When there is a marketable product, small firms face difficulties in finding global sales and
distribution outlets. A 'creative' strategy to overcome these difficulties may be to acquire the sales
department of an established firm including established products in the same field. This is
exemplified by firm C that uses the acquired sales organisation for selling and distributing its own
products. In this particular case, lack of capital has been overcome by paying royalties to the
previous owners of the sales department during a number of years. Furthermore, with regard to the
above mentioned problems in finding qualified personnel, the case studies have brought to light the
strategy of exchange and pooling of personnel between similar firms and research institutes in the
region. This strategy of course, supposes that the start-up is located in a region with a
concentration of bio-medical and pharmaceutical firms, and research institutes.
7. A Focus on Strategic Alliances
An option that may prevent most of the above threats is to enter cooperative alliances with large
pharmaceutical firms (Ernst & Young, 1999; Senker and Sharp, 1997). The evidence in this study
shows various forms of collaboration agreements aimed at improving the financial position of small
firms and their access to marketing and global distribution channels, as well as an expansion of their
R&D activity. One can observe a trend to start collaboration with a Dutch pharmaceutical firm and16
then to add contracts with foreign firms. This points to a cautious learning approach, in which the
small firm first gains experience with the national regulatory environment (such as registration).
Most collaborative agreements are based on complementarity in assets between the two partners.
Thus, in the situation of a small innovative firm seeking finance a large firm often supplies this
finance in return for new product ideas. Although such exchange is the essence of the agreements,
the latter usually includes important side-effects for small firms. Evidence from the United Kingdom
suggests that collaboration with established large firms gives small firms the credibility to raise
further finance (e.g. through the Stock Market) and to develop further collaborations (Senker and
Sharp, 1997). Furthermore, collaboration may have a tremendous impact on learning processes,
such as concerning the way to conduct various stages of clinical trials and understanding of the
market. In addition, the many informal interactions in the large firm's laboratory may lead to
additional learning experiences, for example, in process scale up.
Collaboration with a large pharmaceutical firm is, however, not a bed of roses (Senker and Sharp,
1997). First of all, it is difficult and time-consuming to find the right partner that accepts the specific
terms, unless there is a strong time pressure. Small biotechnology firms increasingly prefer the deals
to be more of a partnership than a supplier-client contract (where payments are merely a fee for
services), thus retaining more rights than previously. Secondly, there is always the question of the
right time to enter an agreement. In some cases, it may be wise to hand over a discovery quite early
in the process, namely before pre-clinical R&D. However, there is a growing belief that the best
stage to leave activities to a big pharmaceutical firm is just before Phase III in clinical trials (a stage
including comprehensive studies required by regulators) (Ernst & Young, 1999). Thirdly, the
agreement may end in an unhappy way, such as in the case of large firms forced to sell most of their
subsidiaries and shares (including those in small firms), due to huge losses from broad
diversification in the past. Another unhappy situation that may be a reason for ending the agreement
is a decreasing commitment of the big firm because the latter has so many other promising projects
in active development.
A final strategy that needs to be mentioned here is full acquisition by the larger firm, while the small17
firm remains relatively independent. This often happens when small firms need huge amounts of
capital in order to establish a manufacturing plant. At the same time, it must be emphasized that a
full acquisition may also lead to the dissolution of  small firms, particularly when they are forced to
integrate activities.
It can be concluded that under particular conditions collaborative agreements satisfy certain basic
needs of small firms, and add to survival by important credibility effects and various learning results.
These findings hold, however, for the short term. It remains unknown under which conditions
collaboration with a large partner leads to a full acquisition and integration on the long run. In
addition, it remains unclear whether the ending of a collaboration brings small firms back into a
weak position.
Table 5 Events and strategies connected with survival (case study evidence)
___________________________________________________________________________
Firm A
Establishment:  in 1989, as a subsidiary; independent since 1994
Activities: basic R&D on transgenic animals and human drugs produced from their milk (a major
success in breeding transgenic animals in 1998)
Successful Strategies
• Fine tuning of financial planning, R&D planning and public relations
• Good position in network of research institutes, enabling joint projects and investment by
others in the firm
• Avoidance of legal barriers by using laboratories in different countries.
Firm B
Establishment: in 1986, independent (with founders experienced in pharmaceutical industry and
process engineering)
Activities (around 1990): mainly R&D, additional manufacturing of monoclonal antibodies, both
on a contract basis
Present Activities: mainly manufacturing of monoclonal antibodies, vaccins and proteins by
contract; additional research on process development by contract.
Strategic Events:18
• 1994, collaboration with large firm (minority share)
• 1996, joining of this firm in order to finance a production facility (remains a stand alone firm)
• 1997, opening of production facility (GMP)
Successful Strategies (present situation):
• Joining of a large firm
• Focus on core competence.
• Operation of  a production facility close to the market (abroad).
Firm C
Establishment: in 1984, independent
Activities (around 1990): R&D (product improvement), manufacturing and sales of therapeutic
drugs against allergy
Present Activities: manufacturing and sales of diagnostics and drugs against allergic disease; design
and sales of bedroom clothing against allergy
Successful Strategies (around 1990):
• Research collaboration (1987/1988) with larger Dutch firms (enabling independent growth)
• Equity capital from flotation on the (non-official) Parallelmarket (since 1986), followed by an
official flotation (1991)
Successful Strategies (present situation):
• Acquisition of sales activity of large company in order to sell own products (in 1991/1992)
• Opening of new production facility (to meet requirements for pharmaceutical registration).
Table 5 Continued
Firm D
Establishment: in 1982, independent (lack of scientific and management background)
Strategic Events:
• 1985/86, through-start, externally financed (various investment companies)
• 1985/86, appointment of managing director (combining biochemical expertise and management
in pharmaceutical industry)
• 1994, bankruptcy
Activities (around 1990): development, manufacturing and (partly) sales of diagnostics
Successful Strategies (around 1990):
• Co-operation with large research laboratories (contracts capital-intensive research to others)
• Collaboration with larger Dutch firms in sales and distribution (since 1986)
Barriers  to Survival (early 1990s):
• Weak financial management (connected with different investors)
• Lack of focus on core competence
• (Hypothetical) too much contracting to others and no solid internal basis.
Firm E
Establishment: in 1986, independent (two founders with scientific expertise)
Strategic Events:
• 1988, collaboration with larger Dutch firm (as majority share holder), mainly for marketing and19
investment reasons (broken in 1990)
• 1992, joining of a larger American firm in the same field (as an independent business unit)
Activities (around 1990): development and manufacturing of ceramic implants
Present Activities: research by contract; manufacturing of ceramic implants and coating of metal
components on customer specification
Successful Strategy (present situation):
• Synergy with American mother company.
_______________________________________________________________________
8. Concluding Remarks
Based on the previous analysis, a number of research paths can be identified. First, the results give
rise to various hypotheses concerning the propensity of small bio-pharmaceutical firms to survive.
These hypotheses address the role of particular strategies in survival, such as team entrepreneurship
(combining expertise), collaborative agreements, and focusing on core-competence. It is necessary
to test hypotheses by using a population of bio-pharmaceutical firms, thus enabling quantitative
modelling. Such research needs also a focus on exploration and testing of the concept of path-
dependency, by identifying the way in which early routines in innovativeness and risk taking
behaviour, etc., have an impact on later performance and survival. A second interesting research
avenue is concerned with the spatial distribution of the sector, particularly the concentration of
firms in Amsterdam and Groningen. In this context, spatial differentiation in the background to new
firm formation and the nature of survival strategies call for attention. The research preferably
includes an analysis of  external economies.
It is now widely accepted that the role of biotechnology in the medical and pharmaceutical
sector will increase in importance and that small firms are a significant element. However,
more than any other type of small high technology firms, bio-pharmaceutical firms are exposed
to high risks. It is therefore, important to further improve the support from the business
environment in the Netherlands. This is the subject of a third research pathway.  It includes
various recommendations for policy studies addressed to the national government and branch
organisations. A major point of attention is the science base in the medical-pharmaceutical
sector. The swift and unexpected shifts in emphasis require an extension of the science base in20
different fields, in order to react efficiently on new developments. This calls for a continuous
monitoring and interpretation of early warning signals in order to adapt the science base in the
best direction, given a relatively small size of the country and limited budgets. A further
important point is the critical availability of management experience. For bio-pharmaceutical
firms without such experience, easy access to management knowledge would be supportive. A
potential way is to establish a pool of experienced managers which advice start-ups on a
regular basis. Another way is training. Quite recently branch organisation NIABA
(Netherlands Biotech Industry Association) has organised a course for researchers seeking an
entrepreneurial career and business people interested in entering biotechnology markets (van
der Meer, 1999). There are a number of other important and broader initiatives in the field,
mainly action lines from the national government aimed at the “protection” of gradual and
solid development paths running from innovative ideas to marketable products. These action
lines include the advancement of applied research, and the stimulation of high value added
investments and university incubators. In addition, there are older (generic) stimulation
instruments available in the system of public loans and subsidies, like a loan that bridges the
stage between start-up and manufacturing firm with a focus on stages close to market introduction
(Technology Development Credit). It is worth monitoring what type of firms emerge from projects
under these supporting policies, what type of existing firms benefit most, and how survival rates
change. A final point that calls for attention is the potential benefits from collaboration with a
larger firm. It would be interesting to identify and test various models of successful collaboration,
for example, regarding timing, precise terms, type of partner, costs and benefits, etc. This requires
to identify the dimensions along which success needs to be measured and the conditions under
which success may arise. Such models serve a better underpinning of collaborative agreements and
accordingly, may contribute to survival of small firms.21
Note 1.
A database could be established by using various sources, i.e. a guide for the biotechnology
industry (Two Rivers, 1999), member lists of branch organisations (pharmaceutical and
biotechnology industry), newspaper coverage, and inquiry by telephone. 
Note 2.
NMAX is the New Market of Amsterdam Exchanges (established in 1997). This is an easily
accessible market aimed at young, fast growing companies. It forms part of a network of similar
markets in Europe.
EASDAQ is a screen based EU regulated stock market (established in Brussels). It also aims at
young, fast growing companies.
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